Hospital Acquired Infection Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, and Others), Infection Type (Urinary Tract Infections, Ventilator-Associated Pneumonia, Surgical Site Infections, Bloodstream Infections, and Other Hospital Infections), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
The global hospital-acquired infection treatment market is expected to reach US$ 19.978 billion in 2030 from US$ 15.099 billion in 2022. The market is estimated to grow with a CAGR of 3.6% from 2022 to 2030.
The key factors driving the market's growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth.
Market Drivers of the Hospital-Acquired Infection Treatment Market
Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report “2020 National and State Healthcare-Associated Infections Progress Report' published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.
Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.
Opportunities in the Hospital-Acquired Infection Treatment Market
The continuous development of novel antimicrobial agents, including antibiotics, antifungals, and antivirals, presents opportunities for combating HAIs, addressing emerging resistance patterns, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets, discovering antibiotics, and developing next-generation infection treatment strategies.
Hospital Acquired Infection Treatment Market: Segmental Overview
The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.
The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.
The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.
Hospital Acquired Infection Treatment Market: Geographical Overview
Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.
In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.
Furthermore, according to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US will increase by 2.7 percent in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3 percent of the nation's Gross Domestic Product. Furthermore, according to the US Department of Health & Human Services, National health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising health expenditure is estimated to increase various funding sources in the research related to the development of HAI drugs, fueling the demand for hospital-acquired infection treatment.
A few of the major primary and secondary sources referred to while preparing the report on the hospital-acquired infection treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).
The key factors driving the market's growth include the high prevalence of hospital-acquired infections (HAI) and the growing focus on patient safety and quality care. However, the threat of antimicrobial resistance hinders market growth.
Market Drivers of the Hospital-Acquired Infection Treatment Market
Central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia are a few examples of healthcare-associated infections (HAIs). These infections can also arise at surgical sites. According to the Centers for Disease Control and Prevention (CDC) report “2020 National and State Healthcare-Associated Infections Progress Report' published in 2021, cases of central line-associated bloodstream infections, Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and ventilator-associated events increased by 24%, 35%, and 15%, respectively, in the US between 2019 and 2020.
Furthermore, According to the January 2022 report from the National Healthcare Safety Network (NHSN), urinary tract infections (UTIs) are the fifth most common type of healthcare-associated infection. UTIs account for more than 9.5% of acute care hospital conditions. Catheter-associated urinary Tract Infection (CAUTI) is caused by urinary catheters used to drain urine from the bladder. CAUTI is one of the most frequent infections among hospitalized UTI patients. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of infections are related to a urinary catheter. During hospital stays, 15% to 25% of hospitalized patients must use urinary catheters. Prolonged urinary catheter use is the most major risk factor for getting CAUTI. CAUTI complications entail patient suffering, prolonged hospital stays, increased treatment costs, and even death.
Opportunities in the Hospital-Acquired Infection Treatment Market
The continuous development of novel antimicrobial agents, including antibiotics, antifungals, and antivirals, presents opportunities for combating HAIs, addressing emerging resistance patterns, and expanding the armamentarium of treatment options. Additionally, collaborative initiatives among healthcare institutions, pharmaceutical companies, and research organizations present opportunities for discovering novel therapeutic targets, discovering antibiotics, and developing next-generation infection treatment strategies.
Hospital Acquired Infection Treatment Market: Segmental Overview
The hospital acquired infection treatment market, by drug class, is segmented into antibacterial, antiviral, antifungal, and others. The antibacterial drugs segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.
The hospital acquired infection treatment market, by infection type, is segmented into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections, and other hospital infections. The urinary tract infections segment held the largest market share in 2022. However, the ventilator-associated pneumonia segment is anticipated to register the highest CAGR from 2022 to 2030.
The hospital acquired infection treatment market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, e-commerce, and others. In 2022, the hospital pharmacies segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.
Hospital Acquired Infection Treatment Market: Geographical Overview
Asia Pacific is estimated to register the highest CAGR from 2022 to 2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the hospital-acquired infection treatment market growth. Developing countries in the region with improving healthcare infrastructure, increasing healthcare expenditure, and a rising focus on adopting advanced medical technologies offer opportunities for market expansion.
In 2022, North America held the largest share of the global hospital-acquired infection treatment market. The US has a high prevalence of HAI, which propels the hospital-acquired infection treatment market growth. As per the CDC, on any given day, about 1 in 31 hospital patients has at least one HAI. Similarly, according to the Office of Disease Prevention and Health Promotion, HAIs and other infections can lead to sepsis, and it causes 1.7 million illness cases and 270,000 deaths per year in the US. Thus, the high prevalence of HAI among people in the US fuels the hospital-acquired infection treatment market growth.
Furthermore, according to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US will increase by 2.7 percent in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Also, health spending accounted for 18.3 percent of the nation's Gross Domestic Product. Furthermore, according to the US Department of Health & Human Services, National health spending is expected to grow at a 5.4% annual rate from 2019 to 2028, and it is expected to reach US$ 6.2 trillion by 2028. The rising health expenditure is estimated to increase various funding sources in the research related to the development of HAI drugs, fueling the demand for hospital-acquired infection treatment.
A few of the major primary and secondary sources referred to while preparing the report on the hospital-acquired infection treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).
1. INTRODUCTION
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
5. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1 Hospital Acquired Infection Treatment - Global Market Overview
6.2 Hospital Acquired Infection Treatment - Global Market and Forecast to 2030
7. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY DRUG CLASS, 2020-2030
7.1 Overview
7.2 Antibacterial Drugs
7.3 Antiviral Drugs
7.4 Antifungal Drugs
7.5 Others
8. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY INFECTION TYPE, 2020-2030
8.1 Overview
8.2 Urinary Tract Infections
8.3 Ventilator-associated Pneumonia
8.4 Surgical Site Infections
8.5 Bloodstream Infections
8.6 Other Hospital Infections
9. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY DISTRIBUTION CHANNEL, 2020-2030
9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 E-Commerce
9.5 Others
10. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
10.1 North America
10.1.1 North America Hospital Acquired Infection Treatment Market Overview
10.1.2 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts to 2030
10.1.3 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Drug Class
10.1.4 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Infection Type
10.1.5 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
10.1.6.1 United States Hospital Acquired Infection Treatment Market
10.1.6.1.1 United States Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.1.2 United States Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.1.3 United States Hospital Acquired Infection Treatment Market, by Distribution Channel
10.1.6.2 Canada Hospital Acquired Infection Treatment Market
10.1.6.2.1 Canada Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.2.2 Canada Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.2.3 Canada Hospital Acquired Infection Treatment Market, by Distribution Channel
10.1.6.3 Mexico Hospital Acquired Infection Treatment Market
10.1.6.3.1 Mexico Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.3.2 Mexico Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.3.3 Mexico Hospital Acquired Infection Treatment Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
10.4.1 South Africa
10.4.2 Saudi Arabia
10.4.3 U.A.E
10.4.4 Rest of Middle East and Africa
10.5 South and Central America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of South and Central America
11. INDUSTRY LANDSCAPE
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - KEY COMPANY PROFILES
13.1 Merck and Co. Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies
13.2 Pfizer Inc
13.3 AbbVie Inc
13.4 Paratek Pharmaceutical Inc
13.5 Eugia US LLC
13.6 Abbott Laboratories
13.7 Cumberland Pharmaceuticals Inc
13.8 Innoviva Specialty Therapeutics Inc
13.9 Cipla Ltd
13.10 Eli Lilly and Company
14. APPENDIX
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
5. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1 Hospital Acquired Infection Treatment - Global Market Overview
6.2 Hospital Acquired Infection Treatment - Global Market and Forecast to 2030
7. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY DRUG CLASS, 2020-2030
7.1 Overview
7.2 Antibacterial Drugs
7.3 Antiviral Drugs
7.4 Antifungal Drugs
7.5 Others
8. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY INFECTION TYPE, 2020-2030
8.1 Overview
8.2 Urinary Tract Infections
8.3 Ventilator-associated Pneumonia
8.4 Surgical Site Infections
8.5 Bloodstream Infections
8.6 Other Hospital Infections
9. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY DISTRIBUTION CHANNEL, 2020-2030
9.1 Overview
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 E-Commerce
9.5 Others
10. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
10.1 North America
10.1.1 North America Hospital Acquired Infection Treatment Market Overview
10.1.2 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts to 2030
10.1.3 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Drug Class
10.1.4 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Infection Type
10.1.5 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hospital Acquired Infection Treatment Market Revenue and Forecasts and Analysis - By Countries
10.1.6.1 United States Hospital Acquired Infection Treatment Market
10.1.6.1.1 United States Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.1.2 United States Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.1.3 United States Hospital Acquired Infection Treatment Market, by Distribution Channel
10.1.6.2 Canada Hospital Acquired Infection Treatment Market
10.1.6.2.1 Canada Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.2.2 Canada Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.2.3 Canada Hospital Acquired Infection Treatment Market, by Distribution Channel
10.1.6.3 Mexico Hospital Acquired Infection Treatment Market
10.1.6.3.1 Mexico Hospital Acquired Infection Treatment Market, by Drug Class
10.1.6.3.2 Mexico Hospital Acquired Infection Treatment Market, by Infection Type
10.1.6.3.3 Mexico Hospital Acquired Infection Treatment Market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Rest of Europe
10.3 Asia-Pacific
10.3.1 Australia
10.3.2 China
10.3.3 India
10.3.4 Japan
10.3.5 South Korea
10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
10.4.1 South Africa
10.4.2 Saudi Arabia
10.4.3 U.A.E
10.4.4 Rest of Middle East and Africa
10.5 South and Central America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Rest of South and Central America
11. INDUSTRY LANDSCAPE
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. HOSPITAL ACQUIRED INFECTION TREATMENT MARKET - KEY COMPANY PROFILES
13.1 Merck and Co. Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies
13.2 Pfizer Inc
13.3 AbbVie Inc
13.4 Paratek Pharmaceutical Inc
13.5 Eugia US LLC
13.6 Abbott Laboratories
13.7 Cumberland Pharmaceuticals Inc
13.8 Innoviva Specialty Therapeutics Inc
13.9 Cipla Ltd
13.10 Eli Lilly and Company
14. APPENDIX
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud
